Patent No. 8,916,588 "Methods of Treatment for Attention Deficit Hyperactivity Disorder" and Patent No. 8,927,010 "Compositions for Treatment of Attention Deficit Hyperactivity Disorder" are owned by Highland’s wholly
The vaccines work of Valera builds on a body of preclinical research at Moderna showing the ability of modified mRNA to express viral antigens in vivo and to
The clinical results reported are from 9 patients, 6 of which carried the worst KS prognosis. Also, 4 of the 9 patients had received from 1 to 8
Danshensu Yibingzhi (IDHP) was developed by Professor Xiaohui Zheng and his research team after 14 years of concerted research effort and was recently approved by the Education Department
The results from the EXPEDITION (including FLIGHT 1, 2 and 3 studies) and GEM clinical trial programs met their primary and secondary endpoints. COPD symptoms can negatively impact
The Committee also recommended approval of the biosimilar for use in all indications included in the reference product’s (Amgen’s NEUPOGEN) label. Highlights Oncologic Drugs Advisory Committee (ODAC) votes
The effort will combine the unprecedented genomic and clinical data from the MMRF’s landmark CoMMpass Study with revolutionary GNS machine learning platforms and rapid computer simulations. The work
In 2013, Ferrer successfully completed a first phase III clinical trial of Ozenoxacin in adult and paediatric patients aged two years and older with impetigo. The study demonstrated
The agreement, which was established in February 2013 and due to expire on December 31, 2015, will now extend to December 31, 2019. Moreover, the payment structure of
The goal of the research collaboration with 23andMe is to study circadian clock genes and ultimately improve therapeutic development for diseases related to molecular clocks. Research into the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.